Credit Suisse Starts AC Immune SA (ACIU) at Outperform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/25/2024
- Wall Street stocks fall as weak GDP growth spreads rate-cut gloom
- Q1 US GDP shows surprise slowing and uncomfortable inflation
- Alphabet (GOOGL) soars 16% on Q1 results beat, first-ever dividend
- Meta shares dip on softer Q2 revenue guidance, elevated AI spending plans
- Oil settles higher as weak U.S. economic growth offset by supply concerns
- IBM tumbles on soft Q1 revenue; announces HashiCorp $6.4bn acquisition
- Hasbro (HAS) brand strength sees earnings top expectations
- Meta Platforms (META) Tops Q1 EPS by 39c, Offers Guidance
- Seagate Technology (STX) Enters $600M Asset Purchase Agreement with Avago
- Rubrik (RBRK) Prices Upsized 23.5M Share IPO at $32/sh
- After-hours movers: Alphabet, Microsoft, Snap, Intel, and more
- Midday movers: Meta, IBM, Caterpillar fall; Chipotle rises
- After-hours movers: Meta, Ford, IBM, ServiceNow and more
- Midday movers: Tesla, Boeing rise; Uber, Old Dominion Freight fall
- After-hours movers: Tesla, Texas Instruments, Seagate, Visa and more
Jefferies Starts AC Immune SA (ACIU) at Buy
October 18, 2016 8:11 AM EDTJefferies initiates coverage on AC Immune SA (NASDAQ: ACIU) with a Buy rating and a price target of $25.00.
Analyst Peter Welford commented, "ACIU may have the broadest Alzheimer's pipeline in biotech, with active & passive therapies targeting both amyloid beta and tau. Crenezumab... More
Leerink Partners Starts AC Immune SA (ACIU) at Outperform
October 18, 2016 6:44 AM EDTLeerink Partners initiates coverage on AC Immune SA (NASDAQ: ACIU) with a Outperform rating and a price target of $22.00.
Analyst Paul Matteis commented, "AC Immune is a biotechnology company that is focused on developing novel medicines for neurodegenerative disorders. ACIU's lead asset crenezumab... More
